• Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

  • Jul 5 2022
  • Durée: 22 min
  • Podcast

Page de couverture de Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • Joseph Mikhael, MD, and Saad Usmani, MD, discuss options in managing triple-class refractory multiple myeloma including selinexor, belantamab mafodotin, and CAR T-cell therapy.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964339). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Multiple Myeloma https://emedicine.medscape.com/article/204369-overview

    Selinexor Prescribing Information https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf

    Belantamab Mafodotin Prescribing Information https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF

    Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview

    Trending Clinical Topic: CAR T-cell Therapy https://reference.medscape.com/viewarticle/965011

    Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor https://www.karyopharm.com/wp-content/uploads/2020/06/Consensus-Recommendations_June2020.pdf

    Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932935/

    Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8038

    Ide-cel Prescribing Information https://packageinserts.bms.com/pi/pi_abecma.pdf

    Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-label, Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(19)30788-0

    DREAMM Trials https://dreammtrials.com/

    Blenrep (Belantamab Mafodotin) REMS https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=403

    Band Keratopathy https://emedicine.medscape.com/article/1194813-overview

    Cilta-cel Prescribing Information https://www.fda.gov/media/156560/download

    BCMA-Directed CAR T-cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04318327
    Voir plus Voir moins
activate_primeday_promo_in_buybox_DT
Voir plus Voir moins

Ce que les auditeurs disent de Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.